Access the full text.
Sign up today, get DeepDyve free for 14 days.
P. Primatesta, N. Poulter (2004)
Lipid levels and the use of lipid-lowering agents in England and ScotlandEuropean Journal of Preventive Cardiology, 11
L. Stokowski (2005)
NATIONAL GUIDELINE CLEARINGHOUSEAdvances in Neonatal Care, 5
T. Ushiroyama, A. Ikeda, M. Ueki (2001)
Beneficial effects of pravastatin in peri- and postmenopausal hyperlipidemic women: a 5-year study on serum lipid and sex hormone levels.Maturitas, 37 3
Jennifer Marcelino, K. Feingold (1996)
Inadequate treatment with HMG-CoA reductase inhibitors by health care providers.The American journal of medicine, 100 6
E. Vartiainen, P. Puska, J. Pekkanen, J. Tuomilehto, P. Jousilahti (1994)
Changes in risk factors explain changes in mortality from ischaemic heart disease in FinlandBMJ, 309
P. Primatesta, N.R. Poulter (2004)
Lipid levels and the use of lipid-lowering agents in England and ScotlandEur J Cardiovasc Prev Rehabil, 11
N.C. Campbell, J. Thain, H.G. Deans (1998)
Secondary prevention in coronary heart disease: baseline survey of provision in general practiceBMJ, 316
W. Insull, M. Davidson, P. Kulkarni, S. Siddhanti, A. Ciaccia, C. Keech (2005)
Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia.Metabolism: clinical and experimental, 54 7
P. Jousilahti, E. Vartiainen, J. Tuomilehto, P. Puska (1999)
Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland.Circulation, 99 9
Pekka Puska, Jukka Salonen, A. Nissinen, Jaakko Tuomilehto (1981)
The North Karelia project.Revue d'epidemiologie et de sante publique, 29 2
R. Oelbaum, D. Galton (1988)
Management of hypercholesterolaemiaCurrent Opinion in Cardiology, 3
G. Engström, B. Hedblad, L. Stavenow, P. Tyden, P. Lind, L. Janzon, F. Lindgärde (2004)
Fatality of Future Coronary Events Is Related to Inflammation-Sensitive Plasma Proteins: A Population-Based Prospective Cohort StudyCirculation: Journal of the American Heart Association, 110
M. Clearfield (2006)
Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women.Current atherosclerosis reports, 8 1
Pekka Jousilahti, Erkki Vartiainen, Juha Pekkanen, Jaakko Tuomilehto, J. Sundvall, Pekka Puska (1998)
Serum cholesterol distribution and coronary heart disease risk: observations and predictions among middle-aged population in eastern Finland.Circulation, 97 11
P. Jousilahti, V. Salomaa, K. Kuulasmaa, M. Niemelä, E. Vartiainen (2005)
Total and cause specific mortality among participants and non-participants of population based health surveys: a comprehensive follow up of 54 372 Finnish men and womenJournal of Epidemiology and Community Health, 59
Who Monica, Principal Investigators (1988)
The World Health Organization MONICA project (monitoring trends and determinants in cardiovascular disease): a major international collabaration
C. Sueta, M. Chowdhury, S. Boccuzzi, Sidney Smith, C. Alexander, Anil Londhe, A. Lulla, R. Simpson (1999)
Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease.The American journal of cardiology, 83 9
D. Wood, G. Backer, O. Faergeman, I. Graham, G. Mancia, K. Pyörälä (1998)
Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention.European heart journal, 19 10
W. Howard (2007)
Low-Fat Dietary Pattern and Risk of Cardiovascular Disease: The Women's Health Initiative Randomized Controlled Dietary Modification TrialYearbook of Endocrinology, 2007
D. Wood, G. Backer, O. Faergeman, I. Graham, G. Mancia, K. Pyörälä (1998)
Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention.Atherosclerosis, 140 2
P. Raggi, M. Davidson, T. Callister, F. Welty, G. Bachmann, H. Hecht, J. Rumberger (2005)
Aggressive Versus Moderate Lipid-Lowering Therapy in Hypercholesterolemic Postmenopausal Women: Beyond Endorsed Lipid Lowering With EBT Scanning (BELLES)Circulation, 112
(2002)
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportCirculation, 106
N. Campbell, J. Thain, H. Deans, L. Ritchie, J. Rawles, Janet Squair (1998)
Secondary prevention clinics for coronary heart disease: randomised trial of effect on healthBMJ, 316
D. Wood (2001)
Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countriesThe Lancet, 357
S. Majumdar, J. Gurwitz, S. Soumerai (1999)
Undertreatment of hyperlipidemia in the secondary prevention of coronary artery diseaseJournal of General Internal Medicine, 14
(2001)
Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce EventsLancet, 357
D. Wood (1998)
European Action on Secondary Prevention by Intervention to Reduce EventsJournal of the American College of Cardiology, 31
A. Nissinen, J. Tuomilehto, P. Puska (1988)
From pilot project to national implementation: experiences from the North Karelia Project.Scandinavian journal of primary health care. Supplement, 1
P. Mcbride, H. Schrott, M. Plane, G. Underbakke, Roger Brown (1998)
Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease.Archives of internal medicine, 158 11
P. Puska, J. Tuomilehto, A. Nissinen, E. Vartiainen (1995)
The North Karelia project : 20 year results and experiences
Diabetes Uk, H. Uk (2005)
JBS 2: Joint British Societies9 guidelines on prevention of cardiovascular disease in clinical practiceHeart, 91
N. Jong, Meri Simojoki, T. Laatikainen, H. Tapanainen, L. Valsta, M. Lahti-Koski, A. Uutela, E. Vartiainen (2004)
The combined use of cholesterol-lowering drugs and cholesterol-lowering bread spreads: health behavior data from Finland.Preventive medicine, 39 5
G. Backer, E. Ambrosioni, K. Borch-Johnsen (2003)
European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other societies on cardiovascular disease prevention and clinical practiceEur J Cardiovasc Prev Rehabil, 10
E. Ganse, L. Laforest, E. Alemao, G. Davies, Stephen Gutkin, D. Yin (2005)
Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) studyCurrent Medical Research and Opinion, 21
E. Vartiainen, P. Jousilahti, G. Alfthan, J. Sundvall, P. Pietinen, P. Puska (2000)
Cardiovascular risk factor changes in Finland, 1972-1997.International journal of epidemiology, 29 1
E. Ganse, T. Souchet, Laurent Laforest, Philippe Moulin, M. Bertrand, P. Jeunne, Noémie Travier, Donald Yin, E. Alemao, G. Pouvourville (2005)
Ineffectiveness of lipid-lowering therapy in primary care.British journal of clinical pharmacology, 59 4
J. Shepherd, C. Packard, T. Iii, J. Walker, E. Stein, Karen Smith, D. Kallend, J. Blasetto (2004)
Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy*Current Medical Research and Opinion, 20
G. Schectman, Jan Hiatt (1996)
Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals.The American journal of medicine, 100 2
S. Wassertheil-Smoller, S. Hendrix, M. Limacher (2003)
Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.JAMA, 289 20
J. Rossouw, G. Anderson, Ross Prentice, Andrea LaCroix, C. Kooperberg, M. Stefanick, R. Jackson, Shirley Beresford, Barbara Howard, Karen Johnson, J. Kotchen, Judith Ockene (2002)
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.JAMA, 288 3
M. Kornitzer, L. Berghmans, M. Wilmet, H. Darquennes, R. Lagasse, R. Payen (1988)
The World Health Organization MONICA Project (Monitoring trends and determinants in cardiovascular disease): A major international CollaborationJournal of Clinical Epidemiology, 41
(1988)
The World Health Organization MONICA Project (Monitoring Trends and Determinants in Cardiovascular Disease): a major international collaboration. WHO MONICA Project Principal InvestigatorsJ Clin Epidemiol, 41
D. Maron, S. Fazio, M. Linton (2000)
Current perspectives on statins.Circulation, 101 2
G. Backer, E. Ambrosioni, K. Borch-Johnsen, C. Brotons, R. Cífková, J. Dallongeville, S. Ebrahim, O. Faergeman, I. Graham, G. Mancia, V. Cats, K. Orth-Gomér, J. Perk, K. Pyörälä, J. Rodicio, S. Sans, V. Sansoy, U. Sechtem, S. Silber, T. Thomsen, D. Wood (2003)
European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.European heart journal, 24 17
S. Hulley, D. Grady, T. Bush (1998)
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal womenJAMA, 280
M. Davidson, K. Maki, S. Karp, Kate Ingram (2002)
Management of Hypercholesterolaemia in Postmenopausal WomenDrugs & Aging, 19
S. Grundy, J. Cleeman, C Noel, B. Merz, H Brewer, L. Clark, D. Hunninghake, R. Pasternak, Sidney Smith, N. Stone (2004)
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.Journal of the American College of Cardiology, 44 3
T. Pearson, I. Laurora, H. Chu, S. Kafonek (2000)
The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.Archives of internal medicine, 160 4
D. Crossman, J. Gibbs, B. Iung, A. Theresa, McDonagh (2005)
JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practiceHeart, 91
E. Sbarouni, P. Flevari, C. Kroupis, Z. Kyriakides, K. Koniavitou, D. Kremastinos (2003)
The Effects of Raloxifene and Simvastatin on Plasma Lipids and EndotheliumCardiovascular Drugs and Therapy, 17
S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs, E. Vittinghoff (1998)
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.JAMA, 280 7
Am J Cardiovasc Drugs 2006; 6 (5): 349-355 ORIGINAL RESEARCH ARTICLE 1175-3277/06/0005-0349/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. Evaluation of Lipid-Lowering Therapy and Cholesterol Goal Attainment in Finland The National FINRISK Study 1 1 2 3 3,4 Evo Alemao, Don Yin, Harri Sintonen, Veikko Salomaa and Pekka Jousilahti 1 Outcomes Research, Merck and Co., Inc., Whitehouse Station, New Jersey, USA 2 Department of Public Health, University of Helsinki, Helsinki, Finland 3 Department of Epidemiology and Health Promotion, National Public Health Institute, Helsinki, Finland 4 School of Public Health, University of Tampere, Tampere, Finland Abstract Background: European and US study findings show that patients in primary care and specialty care are not adequately treated for cholesterol reduction. Objective: To evaluate lipid-lowering treatment in Finland, estimate the proportions of subjects who are achieving cholesterol goals, and assess the influence of determinants on goal attainment. Methods: Subgroup analysis of the FINRISK study, a national study of cardiovascular disease risk factors in Finland. Study participants, the subgroup of patients on lipid-lowering therapy from FINRISK, completed a postal self-administered questionnaire on health/health behavioral factors. Serum total cholesterol (TC) and other clinical variables were measured using a standardized protocol. Ten-year coronary risk
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 20, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.